Q2 sales were slightly ahead of expectations led by continued demand for molecular biology product lines used in COVID-19 testing. However, the momentum decelerated compared to the previous quarter as the situation worsened in the microbiology and immunoassays businesses – due to less patient traffic in hospitals and the resulting decline in routine testing. Though the company witnessed an improvement in these businesses during the last few weeks of Q2, returning to pre-COVID levels cou ....